Artificial riboswitches for gene expression and replication control of DNA and RNA viruses

Significance Riboswitches are short RNA sequences for ligand-dependent modulation of gene expression in cis. This study demonstrates that an artificial riboswitch, a ligand-dependent self-cleaving ribozyme (aptazyme), can knockdown expression of an adeno- (DNA) virus early and a measles (RNA) virus structural gene, impacting biological outcomes, i.e. inhibiting viral genome replication and infectivity, respectively. It is the first report of riboswitches for replication control of human-pathogenic viruses and of their function in fully cytoplasmic (virus) systems. For future applications, aptazymes can be customized in other viruses facilitating analyses of viral gene functions or as a safety switch in oncolytic viruses. Because of their small size and RNA-intrinsic activity, we propose aptazymes as an alternative for inducible promoters in eukaryotic gene expression control. Aptazymes are small, ligand-dependent self-cleaving ribozymes that function independently of transcription factors and can be customized for induction by various small molecules. Here, we introduce these artificial riboswitches for regulation of DNA and RNA viruses. We hypothesize that they represent universally applicable tools for studying viral gene functions and for applications as a safety switch for oncolytic and live vaccine viruses. Our study shows that the insertion of artificial aptazymes into the adenoviral immediate early gene E1A enables small-molecule–triggered, dose-dependent inhibition of gene expression. Aptazyme-mediated shutdown of E1A expression translates into inhibition of adenoviral genome replication, infectious particle production, and cytotoxicity/oncolysis. These results provide proof of concept for the aptazyme approach for effective control of biological outcomes in eukaryotic systems, specifically in virus infections. Importantly, we also demonstrate aptazyme-dependent regulation of measles virus fusion protein expression, translating into potent reduction of progeny infectivity and virus spread. This not only establishes functionality of aptazymes in fully cytoplasmic genetic systems, but also implicates general feasibility of this strategy for application in viruses with either DNA or RNA genomes. Our study implies that gene regulation by artificial riboswitches may be an appealing alternative to Tet- and other protein-dependent gene regulation systems, based on their small size, RNA-intrinsic mode of action, and flexibility of the inducing molecule. Future applications range from gene analysis in basic research to medicine, for example as a safety switch for new generations of efficiency-enhanced oncolytic viruses.

[1]  A. Melcher,et al.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Markus Wieland,et al.  Artificial Riboswitches: Synthetic mRNA‐Based Regulators of Gene Expression , 2008, Chembiochem : a European journal of chemical biology.

[3]  RNA Polymerase II-Controlled Expression of Antigenomic RNA Enhances the Rescue Efficacies of Two Different Members of the Mononegavirales Independently of the Site of Viral Genome Replication , 2006, Journal of Virology.

[4]  R. Breaker,et al.  Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches , 2009, Gene Therapy.

[5]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Schneider‐Schaulies,et al.  RNA Interference with Measles Virus N, P, and L mRNAs Efficiently Prevents and with Matrix Protein mRNA Enhances Viral Transcription , 2006, Journal of Virology.

[7]  K. Sada,et al.  Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference , 2006, Antiviral Research.

[8]  Simon Ausländer,et al.  A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression. , 2010, Molecular bioSystems.

[9]  S. Russell,et al.  ONCOLYTIC VIROTHERAPY , 2012, Nature Biotechnology.

[10]  B. Berkhout,et al.  RNA interference against viruses: strike and counterstrike , 2007, Nature Biotechnology.

[11]  Laising Yen,et al.  Engineering high-speed allosteric hammerhead ribozymes , 2007, Biological chemistry.

[12]  Maria C. DeRosa,et al.  Challenges and Opportunities for Small Molecule Aptamer Development , 2012, Journal of nucleic acids.

[13]  Chiocca Ea.  The host response to cancer virotherapy. , 2008 .

[14]  T. Lion,et al.  Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery , 2012, Antiviral research.

[15]  R. D'Amato,et al.  Exogenous control of mammalian gene expression through modulation of RNA self-cleavage , 2004, Nature.

[16]  Markus Wieland,et al.  Improved aptazyme design and in vivo screening enable riboswitching in bacteria. , 2008, Angewandte Chemie.

[17]  Christina D Smolke,et al.  Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems , 2010, Proceedings of the National Academy of Sciences.

[18]  H. Fechner,et al.  Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. , 2011, Human gene therapy.

[19]  C. von Kalle,et al.  MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  R. Cattaneo,et al.  Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. , 2006, Cancer research.

[21]  S. Russell,et al.  Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting , 2009, Journal of Virology.

[22]  R R Breaker,et al.  Rational design of allosteric ribozymes. , 1997, Chemistry & biology.

[23]  Roberto Cattaneo,et al.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded , 2008, Nature Reviews Microbiology.

[24]  Markus Wieland,et al.  Artificial ribozyme switches containing natural riboswitch aptamer domains. , 2009, Angewandte Chemie.

[25]  R. Alemany,et al.  The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Yohei Yokobayashi,et al.  Controlling Mammalian Gene Expression by Allosteric Hepatitis Delta Virus Ribozymes , 2013, ACS synthetic biology.

[27]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[28]  R. Breaker,et al.  Engineering precision RNA molecular switches. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Enk,et al.  Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. , 2013, The Journal of investigative dermatology.

[30]  M. Famulok,et al.  Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy , 2007 .

[31]  Xiaomin Wang,et al.  Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication‐competent CD95L adenovirus , 2009, Experimental dermatology.

[32]  Xiaomin Wang,et al.  Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions. , 2010, Antiviral research.

[33]  D. Nettelbeck,et al.  Insulated hsp70B′ promoter: stringent heat‐inducible activity in replication‐deficient, but not replication‐competent adenoviruses , 2008, The journal of gene medicine.

[34]  M. Billeter,et al.  Rescue of measles viruses from cloned DNA. , 1995, The EMBO journal.

[35]  Yohei Yokobayashi,et al.  Synthetic mammalian riboswitches based on guanine aptazyme. , 2012, Chemical communications.

[36]  M. Win,et al.  A modular and extensible RNA-based gene-regulatory platform for engineering cellular function , 2007, Proceedings of the National Academy of Sciences.

[37]  Beatrix Suess,et al.  Selection of tetracycline inducible self-cleaving ribozymes as synthetic devices for gene regulation in yeast. , 2011, Molecular bioSystems.

[38]  S. Haas,et al.  Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses , 2012, Nucleic acids research.

[39]  R. Cattaneo,et al.  Attenuation of V- or C-Defective Measles Viruses: Infection Control by the Inflammatory and Interferon Responses of Rhesus Monkeys , 2008, Journal of Virology.

[40]  R. Cortese,et al.  Gene therapy progress and prospects: transcription regulatory systems , 2004, Gene Therapy.

[41]  Michael Famulok,et al.  Aptamers for allosteric regulation. , 2011, Nature chemical biology.

[42]  K. White,et al.  Riboswitching on RNA virus replication , 2007, Proceedings of the National Academy of Sciences.

[43]  Christina D Smolke,et al.  Synthetic RNA switches as a tool for temporal and spatial control over gene expression. , 2012, Current opinion in biotechnology.

[44]  Ronald R. Breaker,et al.  Engineered allosteric ribozymes that sense the bacterial second messenger cyclic diguanosyl 5'-monophosphate. , 2012, Analytical chemistry.

[45]  S. Russell,et al.  Engineering microRNA responsiveness to decrease virus pathogenicity , 2008, Nature Medicine.

[46]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[47]  E. Chiocca.  The host response to cancer virotherapy. , 2008, Current opinion in molecular therapeutics.

[48]  Markus Wieland,et al.  Engineering of ribozyme-based riboswitches for mammalian cells. , 2012, Methods.